Loss-of-Function and Gain-of-Function Mutations

Loss-of-function and gain-of-function describe the two broad ways a mutation can change what a gene product does. A loss-of-function variant reduces or abolishes the normal activity of a gene, while a gain-of-function variant confers a new or enhanced activity. The distinction is central to variant interpretation because the expected mechanism for a given gene determines which kinds of variant are plausibly disease-causing.

Definition

A loss-of-function mutation decreases or eliminates the normal function of a gene product, whereas a gain-of-function mutation produces a new or increased activity; the two define opposite functional consequences used to reason about a variant's plausibility and mode of action.

Scope

The entry explains the two mechanism classes and their sub-types — including haploinsufficiency and dominant-negative effects on the loss side and activating or neomorphic effects on the gain side — and why mechanism is built into classification reasoning. It is a methodological and conceptual topic, not clinical guidance.

Core questions

• How do loss-of-function and gain-of-function variants differ at the molecular level?
• What are haploinsufficiency, dominant-negative, activating, and neomorphic effects?
• Why does the expected mechanism of a gene constrain which variants are interpreted as pathogenic?
• How is mechanism evidence used within variant classification frameworks?

Key concepts

• Loss of function
• Gain of function
• Haploinsufficiency
• Dominant-negative effect
• Activating (constitutive) mutation
• Neomorphic activity
• Mechanism-specific interpretation

Mechanisms

Loss-of-function variants — nonsense, frameshift, canonical splice-site, or deleterious missense changes — lower the amount or activity of a gene product; when a single working copy is insufficient, the result is haploinsufficiency, and a mutant product that interferes with the normal one produces a dominant-negative effect. Gain-of-function variants instead make a product constitutively or excessively active (activating mutations) or give it an entirely new activity (neomorphic mutations). The expected mechanism is gene-specific: tumour-suppressor genes typically act through loss of function while oncogenes act through gain of function, a contrast emphasised in surveys of cancer genomes (Vogelstein et al., 2013). Whether a gene is intolerant to loss of function is now quantified by population constraint metrics (Karczewski et al., 2020), and classification frameworks use mechanism explicitly — for instance, weighting a predicted null variant as strong evidence only when loss of function is an established disease mechanism for that gene (Richards et al., 2015).

Clinical relevance

Knowing whether a gene causes disease through loss or gain of function shapes how variants in that gene are interpreted and reported, which is part of appraising molecular findings. The entry explains the mechanistic concepts behind interpretation; it does not provide individualised assessment or treatment guidance.

Evidence & guidelines

Mechanism is embedded in the ACMG/AMP germline classification rules, where predicted loss-of-function evidence is weighted according to the established mechanism of the gene (Richards et al., 2015). Cancer genome surveys characterise the loss-of-function tumour-suppressor versus gain-of-function oncogene contrast (Vogelstein et al., 2013), and constraint data quantify intolerance to loss of function across genes (Karczewski et al., 2020).

History

The functional dichotomy was articulated in classical genetics through allelic series describing amorphic, hypomorphic, antimorphic, and neomorphic alleles, and was later mapped onto molecular mechanisms as gene function was characterised. Genome-scale sequencing then allowed loss-of-function tolerance to be measured directly across the genome (Karczewski et al., 2020).

Debates

How should predicted loss-of-function variants be weighted when the gene's mechanism is uncertain?

Strong evidence for pathogenicity from a predicted null variant depends on loss of function being an established disease mechanism for that gene; when the mechanism is unclear or the gene tolerates loss of function, the same variant carries far less interpretive weight.

Seminal works

• vogelstein-2013
• karczewski-2020

Frequently asked questions

What is the difference between loss-of-function and gain-of-function mutations?

A loss-of-function mutation reduces or removes a gene product's normal activity, while a gain-of-function mutation gives the product new or increased activity; they represent opposite functional consequences.

Why does the gene's mechanism matter for interpreting a variant?

A predicted null (loss-of-function) variant is strong evidence for pathogenicity only when loss of function is an established disease mechanism for that gene; in genes that act through gain of function or that tolerate loss of function, the same variant is interpreted very differently.